Siponimod (also known as BAF312 or Mayzent) is a tablet being developed for secondary progressive MS by Novartis Pharmaceuticals. It was licensed by the European Medicines Agency (EMA) on Monday 20 January 2020.

This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by making a donation to pay for the server costs.